507 Economic impact of the Cystic Fibrosis management guideline implementation in one region of France  by Huot, L. et al.
Sl12 
[ ]Change in cost of care, clinical condition and life expectancy of 
patients with Cystic Fibrosis in Moscow (Russia) over a ten year 
period 
N. Kashirskaya, J. Vasilieva, N. Kapranov, A. Voronkova, Y. Mizernitsky. Research 
Centre for Medical Genetics RAMS, Moscow, Russia 
Advances in the treatment and management of respiratory and pancreatic disorders 
have dramatically increased the life expectancy of CF patients. The aim of this 
study was to evaluate the influence of the introduction of modern therapies on cost 
of pharmacologic treatment, clinical status and life expectancy of CF patients in 
Moscow over a ten year period. 
Methods: Medical records of patients in 1993 1994 (I period 35 subjects), 1997 
1998 (II period 66) and 2003~004 (III period 87) were analysed. In 1993 
pancreatic enzymes (Creon) were introduced into the treatment regimen, in 1998 
Dornase alfa and ceftazidime, in 2003 cefepime and meropenem. In 1998 home 
IV treatment for planned antibiotic courses was started. 
Results: The annual cost of pharmacologic treatment of our patients in I, II, 
III periods was 1809.8, 4266.7 and 23,830.8 US dollars correspondingly. Of total 
costs 83, 35 and 9%% were from pancreatic enzymes; 17, 13 and 2%% from 
drugs classified as "other"; 0, 30, 72%% were from Dornase alfa; 0, 22, 16%% 
from mentioned antibiotics. Cost of home IV antibacterial therapy compared with 
inpatient was four times higher. Introduction of new therapies and ways of care were 
followed by the considerable increased life expectancy especially between I and II 
periods (16 and 27.9yrs) and increased number of patients >18yrs old (10.3%, 
18.7% and 31.7%). Severity of disease, patients' age and chronic Ps.aeruginosa 
infection were important determinants of pharmacologic treatment cost. 
Conclusions: A greater number of studies should be performed to determine costs 
(including indirect costs and patient costs) and outcomes of therapies applied under 
everyday life conditions for patients with CE 
13. Other issues 
~8]  Collective therapeutic education for Cystic Fibrosis children in 
Nantes (France) 
V David, C. Berville, R Douaud, V Dumas, C. Greffier, R Leger, A. Marion, U. de 
Pontbriand, Multisciplinary Team of Children's CRCM Nantes. 1 CRCM Enfants 
HME Quai Moncousu, 44093 Nantes', France 
Introduction: Efficacy of therapeutic education has been proved particularly in 
diabetes and asthma. Therapeutic education is a new approach for patients with 
cystic fibrosis. Individual or collective sessions may be proposed. Problems for 
collective sessions in cystic fibrosis are important because of risk of cross infection. 
Advantages are evident: group dynamism, interactivity, peer exchanges. 
Methods: We offered five ten years old children and their parents to take part 
in three afternoons. Strict hygiene instructions were set. During each afternoon, 
children were placed on carpets with a little table for each one and pens, notebooks. 
Children were separated by signalization on floor and had to wear a face-mask if
they move out of the security perimeter. During the first afternoon, children met and 
told each other their typical day. This helped caregivers to establish for each child 
their educative diagnosis. Parents were in another room and worked about educative 
diagnosis with concept mapping. Afterwards, learning objectives were determined 
for children and adults. In-between, a break with sporting activities (badminton) was 
proposed to children. During the second afternoon, security objectives were tackled: 
these objectives are: to mark pulmonary exacerbations signs and act; to mark fat in 
alimentation and adjust pancreatic enzymes. Interactive and playful activities were 
offered to children. Same subjects were worked separately with parents. Evaluation 
of acquired know ledges was done during the third afternoon. 
Conclusion: Families were very enthusiastic. Exchanges were dynamic and rich. 
Two observers were present to help caregivers improve their pedagogy. 
•]  Economic impact of the Cystic Fibrosis management guideline 
implementation in one region of France 
L. Huot 1 , S. Touzet 1, I. Durieu 2, G. Bellon 3, R. Nove-Josserand 2, C. Colin 1 . 
l Injbrmation mddicale, Hospices Civils de Lyon, 2Mddecine Interne, Centre 
Hospitalier Lyon Sud, 3pddiatrie, H@ital Debrousse, Lyon, France 
Aims: To evaluate how French national guidelines on Cystic Fibrosis (CF) man- 
agement, implemented in 2002, had impacted CF-related costs. 
Methods: The analysis of direct medical costs was done in 2000 (before guideline 
implementation) and in 2003 (after implementation) from the point of view of the 
French national healthcare insurance system. The patients, i.e. 65 in 2000 and 64 in 
2003, were followed-up in the regional CF reference center (CFRC). We quantified 
CF-related home and hospital care costs. The data on medical practices and costs 
came from a patient-completed questionnaire, the health-care insurance database, 
the CFRC database, the French hospital claims database and the regional home 
medical care association database. 
Results: We found an average cost of e16,474/patient/year in 2000, and e22,725 
in 2003 (based on the 2003 value of the euro). Inpatient medical care increased 
from 15% of the total cost in 2000 to 22% in 2003. Medication accounted for 45% 
of the total cost for the two periods, with an average cost of e7229/patient/year in 
2000 and e10,336 in 2003. Rh-DNase accounted for 23% of the total cost for the 
two periods, and inhaled tobramycin i creased from 7% of the total cost in 2000 
to 15% in 2003. Home intravenous antibiotic treatments accounted for 20% of the 
total cost for the two periods. 
Conclusions: We highlighted an increase in CF care costs between 2000 and 
2003, which might be related to the changes in practices caused by guideline 
implementation i.e. the use of new medication (rh-DNase and tobramycin) and 
more frequent follow-up in the CFRC. We noticed an emphasis on home health 
care notably for intravenous antibiotic treatments. 
~9]  Information and communication system for CF care: gathering 
actions and assistance 
G. Rault 1 , L. Gu6ganton 1 , S. Ravilly 3, E. Bonomo 3, G. Jan 4, R Traineau 3.
1Coordination Cell of the CF Western Health Network, Roscoff 2Vaincre la 
Mucoviscidose; 3 CATEL; 4 0GGAM, France 
Care for CF patients needs coordinated management and multiple health profession- 
als working in different fields and settings. Information has to be shared by multiple 
recipients. Often the network can be hampered by the large amount of information 
to share. Despite the enormous advances in information and communication 
technologies, networks need to be structured and organized in an optimized way 
to help health professionals improve CF care and quality of life of patients and 
their family. To succeed, one needs to identify every participant to the network, its 
role and information shared in order to propose tools and methods adapted to the 
information system. It is a question of setting up a method to manage projects and 
help to decide. Therefore the Association ~ Vaincre la Mucoviscidose ~decided to 
mutualize thoughts and works already engaged by some CF centres and interregional 
CF networks. This experience will be presented: 
The content of expert assistance: creation and animation of pilot groups, working 
groups, decision making helps, writing of functional specifications, exchanges 
with the network members, follow up of technical starting up; 
Coherence and articulation between conducted actions at different levels: CF 
centre, CF network, National CF Association; 
Concrete applications installed or considered: electronic patient chart, interface 
between ational and European registry, web site, secure e-mail, telestafl; tele 
education, running of database for research purpose. 
International collaborations are considered with other regional and national experi- 
ences. 
